ArticleZoological research2026
A secretion-deficient DENV1 DNA vaccine induces durable immunity and confers protection against DENV2.
Article in Zoological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-dependent enhancement (ADE) remains a major obstacle to dengue virus (DENV) vaccine development and continues to make safe, broadly protective vaccination a global health priority (Aggarwal et al., 2024; Halstead et al., 2014; Martinez et al., 2021; Paz-Bailey et al., 2024; Shepard et al., 2016). This study generated two DNA-based DENV vaccine constructs encoding premembrane (prM) and envelope (E) proteins: a secretion-deficient mutant (DNSP) and a full-length wild-type (WT) prM-E protein. Both vaccines elicited cell-mediated immune responses and protected mice against lethal DENV1 challenge. DNSP immunization induced minimal anti-prM-E antibody production but conferred durable protection, as evidenced by sustained T cell responses and challenge experiments performed one year after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.